KOMZIFTI® (Ziftomenib)

The FDA on November 13, 2025, approved KOMZIFTI®, a menin inhibitor, for adults with relapsed or refractory Acute Myeloid Leukemia (AML) with a susceptible Nucleophosmin 1 (NPM1) mutation who have no satisfactory alternative treatment options. KOMZIFTI® is a product of Kura Oncology, Inc.